Request Trial
15 December 2024NewsAmericasChristopher Sweeney Executive Director Acuitas Therapeutics, Alison Maddeford Director Litigation & Risk Management Thermo Fisher Scientific, Daniel Yarbrough Head of Intellectual Property Element Biosciences, Madhuri Roy Partner Cooley

WATCH: The challenge of protecting patents and innovation - obviousness-type double patenting post In re Cellect

Speakers from Acuitas Therapeutics, Thermo Fisher Scientific, Element Biosciences, and Cooley examine the risks and implications of obviousness-type double patenting and offer guidance for mitigating its impact on innovation.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Novo ends Hims & Hers dispute with deal for blockbuster weight-loss drugs
10 March 2026   The telehealth platform’s shares jumped more than 40% after the news that it will sell Ozempic and Wegovy—and no longer faces a lawsuit from the Danish pharma giant.
Americas
Medtech Magnolia fails to revive $2.1m verdict at Fed Circ
9 March 2026   Appeals court upholds lower court’s ruling, clarifying key legal questions concerning patent claims for blood‑testing devices.
Americas
Nomination call: Influential Women in IP list closes ahead of International Women’s Day
6 March 2026   With IWD approaching, WIPR urges practitioners to submit nominations for its Influential Women in IP list, recognising outstanding female leaders across the profession.


Editor's picks

Abbott IP chief: ‘Firms without AI policies scare me’
Americas
Abbott IP chief: ‘Firms without AI policies scare me’
5 March 2026

Editor's picks

Americas
Abbott IP chief: ‘Firms without AI policies scare me’
5 March 2026
Americas
SCOTUS flooded with briefs calling for reversal of ‘skinny label’ ruling
26 February 2026
Americas
Eli Lilly escapes $278m payout in biotech licensing dispute
26 February 2026
Americas
Novo Nordisk takes on Hims & Hers after $49 pill ‘turnaround’
10 February 2026
Asia
AstraZeneca partners with Chinese firm ahead of next obesity race
5 February 2026
Americas
The quantum advantage: IP considerations for the next generation of life sciences innovation
27 January 2026

More features

GSK inks licensing deal for liver disease drug
Arnold & Porter adds tech litigator in San Francisco
Novo ends Hims & Hers dispute with deal for blockbuster weight-loss drugs
UKIPO extends funding for specialist IP crime unit as counterfeit risks grow
Medtech Magnolia fails to revive $2.1m verdict at Fed Circ
Nomination call: Influential Women in IP list closes ahead of International Women’s Day
Abbott IP chief: ‘Firms without AI policies scare me’
Moderna inks billion-dollar deal to settle long-running Spikevax dispute